News
-
Amneal Pharmaceuticals has announced the launch of a generic beclomethasone MDI and a generic albuterol MDI in the US, noting that these are its first metered dose inhalers in the US market. The company had… Read more . . .
-
DPI developer Iconovo has announced that interim CEO Anders Månsson will be the company’s permanent CEO. Månsson was named interim CEO at the end of October 2025, afterJohan Wäborg announced that he would step down. He had… Read more . . .
-
Oragenics said that it has initiated a Phase 2a trial of ONP-002, a dry powder intranasal neurosteroid, for the treatment of mild traumatic brain injury in Australia after receiving approval from the Human Research Ethics… Read more . . .
-
Device company Nemera and UK-based pharma company Therakind have announced a deal that will allow Nemera to add Therakind’s DriDose intranasal dry powder delivery technology to its portfolio. Therakind, which is developing several nasal DPI products… Read more . . .
-
According to Savara, the MHRA has accepted the company’s marketing application for Molbreevi molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis for accelerated review, with a decision expected by the end of… Read more . . .
-
Glenmark Pharmaceuticals announced that it will now directly commercialize and distribute Ryaltris olopatadine / mometasone nasal spray in the US. Hikma acquired US rights to Ryaltris in February 2020 and launched the nasal spray in the… Read more . . .
-
SMI developer Resyca has announced the appointment of former Proveris Scientific Sales Director for Europe and India Deborah Jones as its new CEO, following the resignation of Remko Beimers. Jones joined Proveris in 2016 after… Read more . . .
-
The 2026 edition of the Respiratory Drug Delivery conference, organized by RDD Online, will take place May 10-14 at the Westin Kierland Resort in Scottsdale, AZ, USA. RDD Online’s Richard Dalby says that organizers expect… Read more . . .
-
Belgian biotech Cannovex and Dutch DPI developer PureIMS announced that Cannovex has acquired exclusive rights to develop pharmaceutical cannabinoid products delivered via PureIMS’s Cyclops high-dose dry powder inhaler. The companies say that they have entered… Read more . . .
-
According to Dompé, researchers at the Agostino Gemelli IRCCS University Hospital in Rome, Italy have initiated a Phase 2 trial of Dompé’s intranasal formulation of cenegermin-bkbj, a recombinant human nerve growth factor, in patients with… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland